Tues, 5/3: 2022 ISCT Commercialization Signature Series
Katy Spink spoke in Session 1 of the 2022 Signature Series

Wed, 5/4: Roundtable Room 6
Kevin Whittlesey spoke on "Debating the Acceptable Risk of AAV-Based Genomic Integration"

Thurs, 5/5:
Katy Spink spoke again, as part of "Where Cells Thrive – Scalability and Flexibility in Bioreactor Technology."

Reach out to us via the partnering system

And/or reach out to the BD team here